WO2021243526A1 - 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用 - Google Patents

新生儿肠外营养相关性肝病特异性标志物lncRNA的应用 Download PDF

Info

Publication number
WO2021243526A1
WO2021243526A1 PCT/CN2020/093802 CN2020093802W WO2021243526A1 WO 2021243526 A1 WO2021243526 A1 WO 2021243526A1 CN 2020093802 W CN2020093802 W CN 2020093802W WO 2021243526 A1 WO2021243526 A1 WO 2021243526A1
Authority
WO
WIPO (PCT)
Prior art keywords
lncrna
liver disease
parenteral nutrition
expression
neonatal
Prior art date
Application number
PCT/CN2020/093802
Other languages
English (en)
French (fr)
Inventor
朱雪萍
朱晓黎
刘刚
何山
耿海峰
王华伟
伍高红
吴志新
陈财龙
Original Assignee
苏州大学附属儿童医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州大学附属儿童医院 filed Critical 苏州大学附属儿童医院
Priority to PCT/CN2020/093802 priority Critical patent/WO2021243526A1/zh
Publication of WO2021243526A1 publication Critical patent/WO2021243526A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the invention relates to the technical field of molecular biology, in particular to the application of a specific marker lncRNA for neonatal parenteral nutrition-related liver disease.
  • lncRNA is a type of non-coding RNA product with a transcript length greater than 200bp. It regulates various life activities such as embryonic development, cell proliferation, transfer and differentiation at multiple levels such as transcription, post-transcription and chromosome modification. Its abnormal expression is associated with various The occurrence and development of diseases are closely related.
  • LncRNA has tissue specificity and spatio-temporal specificity. The expression level of lncRNA is different between different tissues. The expression level of lncRNA in the same tissue or organ at different growth stages will also change. LncRNA can be reshaped from chromatin, transcriptional regulation and transcription Various levels such as post-processing realize the regulation of gene expression.
  • the lncRNA promoter can also bind transcription factors, such as Oct3/4, Nanog, CREB, Sp1, c-myc, Sox2, and p53. Local chromatin histones also have characteristic modification methods and structural features, with low sequence conservation. Only about 12% of lncRNA can be found in other organisms other than humans. Its mechanism of action is very complicated and has not yet been fully understood. For example, many studies have confirmed that miRNAs are involved in regulating the expression of TGF ⁇ and the process of EMT, but are involved in this process. The lncRNA is not clear. In addition, some online websites such as starBase 2.0 have a low prediction accuracy rate. For example, GAS5 and miRNA21, which are relatively clear now, cannot be predicted, and there are as many as 1,400 lncRNAs in human serum, and there are changes that make lncRNAs unable to be used effectively.
  • transcription factors such as Oct3/4, Nanog, CREB, Sp1, c-myc, Sox2, and
  • PN Parenteral nutrition
  • PNALD Total parenteral nutrition-associated liver disease
  • PNALD is a major disease that seriously threatens the health of newborns. How to prevent and treat this disease is the clinical Problems to be solved.
  • the main clinical manifestations of PNALD are jaundice, hepatosplenomegaly, kaolin-like stools, and laboratory tests such as liver function often suggest alanine transferase, aspartate transferase, alkaline phosphatase, total blood bilirubin, Direct bilirubin is elevated.
  • the invention provides an lncRNA as a specific marker for neonatal parenteral nutrition-related liver disease and its application.
  • the present invention discloses for the first time lncRNA G034337 as a specific marker for neonatal parenteral nutrition-related liver disease. It uses whole blood specimens that are relatively easy to obtain directly in clinical practice, combined with a designed primer pair to perform qRT-PCR to verify the differential expression of lncRNA, which has rapid , Simple, time-saving, high detection sensitivity, less sample consumption, is an accurate and specific method for the diagnosis of neonatal parenteral nutrition-related liver disease.
  • lncRNA as a specific marker for neonatal parenteral nutrition-related liver disease; the lncRNA is lncRNA G034337.
  • the lncRNA is lncRNA G034337.
  • the lncRNA is lncRNA G034337.
  • the neonatal parenteral nutrition-related liver disease can be diagnosed, which is consistent with the results of existing clinical detection methods.
  • the present invention discloses a diagnostic kit for neonatal parenteral nutrition-related liver disease.
  • the kit contains a reagent capable of quantifying the expression of lncRNA.
  • the lncRNA is lncRNA G034337; preferably, the expression of lncRNA can be measured
  • the quantitative reagent includes a qRT-PCR primer pair; the sequence of the qRT-PCR primer pair is SEQ ID NO:1 and SEQ ID NO:2.
  • the invention also discloses the application of a neonatal parenteral nutrition-related liver disease diagnosis kit in the preparation of a neonatal parenteral nutrition-related liver disease diagnosis reagent.
  • the kit contains a reagent capable of quantifying the expression of lncRNA, and the lncRNA It is lncRNA G034337; preferably, the reagent capable of quantifying the expression of lncRNA includes a qRT-PCR primer pair; the sequence of the qRT-PCR primer pair is SEQ ID NO: 1 and SEQ ID NO: 2.
  • the invention discloses the application of a reagent capable of quantifying the expression of lncRNA in the preparation of a diagnostic kit for neonatal parenteral nutrition-related liver disease or a reagent capable of quantifying the expression of lncRNA in the preparation of neonatal parenteral nutrition.
  • the lncRNA is lncRNA G034337; preferably, the reagent capable of quantifying the expression of lncRNA includes a qRT-PCR primer pair; the sequence of the qRT-PCR primer pair is SEQ ID NO: 1. SEQ ID NO: 2.
  • the present invention extracts total RNA from whole blood samples of neonatal parenteral nutrition-related liver disease patients and healthy controls, designs qRT-PCR specific primers, and detects the expression of specific lncRNA G034337 by conventional qRT-PCR
  • the results showed that the expression of lncRNA G034337 was significantly up-regulated in children with neonatal parenteral nutrition-related liver disease; this shows that by detecting the expression level of lncRNA G034337, it is possible to effectively distinguish infants with parenteral nutrition-related liver disease And normal healthy people.
  • sequence of lncRNA G034337 is SEQ ID NO: 3, which is specifically as follows:
  • the relative expression level of lncRNA is analyzed using GraphPad Prism 5 software, using single sample T test and independent sample T test in the software.
  • P ⁇ 0.05 the result is considered to be statistically significant.
  • P ⁇ 0.01 the result is There is a very significant difference in statistics.
  • Figure 1 is a diagram showing the differential expression of lncRNA G034337 between patients in the PNALD group and normal healthy people;
  • Figure 2 is a diagram showing the differential expression of lncRNA G034337 between neonatal hyperbilirubinemia patients and normal healthy people;
  • Figure 3 is a diagram showing the differential expression of lncRNA G034337 between fatty liver children and normal healthy people.
  • RNA extraction kit was purchased from Ambion; qRT-PCR reverse transcription kit was purchased from Fermentas; SYBR system Mix was purchased from TaKaRa Bioengineering (Dalian) Co., Ltd.; 384-well plates and membranes were purchased from Roche.
  • Example 1 The expression of lncRNA G034337 in neonatal parenteral nutrition-related liver patients was significantly up-regulated
  • the qRT-PCR primers are:
  • the amplification curve is smooth and as the number of cycles increases, the fluorescence signal has a clear logarithmic phase.
  • the blank control has no continuous curve generation, indicating that the amplification is good.
  • TRIzol Reagent samples containing leukocytes from neonatal patients with parenteral nutrition-related liver disease and healthy controls were taken out at -80°C and dissolved naturally at 4°C; an equal volume of phenol chloroform was added and centrifuged at maximum speed for 5 minutes at room temperature. Take the supernatant; add 1.25 times the volume of 100% ethanol; add the mixed solution to the column, room temperature, 13000rpm, 30s, discard the flow-through solution; add 350 ⁇ L miRNA Wash Solution 1 (mirVana TM miRNA ISOlation Kit, Ambion-1561) to the spin column Medium, 13000rpm, 30s.
  • miRNA Wash Solution 1 mirVana TM miRNA ISOlation Kit, Ambion-1561
  • RNA samples Take 1.0 ⁇ L of total RNA samples from neonatal patients with parenteral nutrition-related liver disease and healthy controls, and measure the OD value with the Agilent bioanalyzer nanodrop-2000, and measure the A260/A280 value on the UV spectrophotometer.
  • the total RNA concentration is Between 5-10ng/ ⁇ L, the value of A260/A280 is between 1.2-1.9, which means that the purity of total RNA is good, and there is no pollution of protein or other organic matter and no total RNA degradation.
  • the diagnostic kit for neonatal parenteral nutrition-related liver disease qRT-PCR specific lncRNA related to neonatal parenteral nutrition-related liver disease
  • Reverse transcription was performed with Fermentas reverse transcription kit.
  • Reverse transcription reaction system total RNA 2.5 ⁇ L, RNase inhibitor RRI 0.25 ⁇ L, dNTP (10mM each) 0.5 ⁇ L, 5 ⁇ M-MuLV buffer 1.0 ⁇ L, random primer ( 2 ⁇ M) 0.5 ⁇ L, M-MuLV reverse transcriptase 0.25 ⁇ L, total volume 5 ⁇ L. It is carried out in two steps, the first step: 65°C, 5min; on ice, 10min; the second step: 42°C, 60min; 70°C, 15min; after the reaction is completed, store in -80°C refrigerator.
  • QRT-PCR system ddH 2 O7 ⁇ L, SYBR system Mix 10 ⁇ L, 50*ROX refenence dye 0.4 ⁇ L, upstream primer (10 ⁇ M)/downstream primer (10 ⁇ M) 0.8 ⁇ L, template cDNA 1 ⁇ L, total volume 20 ⁇ L; after mixing, centrifuge and place in ABI Fluorescence quantitative PCR reaction was performed in 7500, and the reaction parameters were set as follows: 95°C for 30s, then 95°C for 5s, 60°C for 31s, a total of 40 cycles.
  • ⁇ -actin is used as the internal reference gene, and the target gene is normalized to ensure that the amount of target gene is compared in an equal number of samples.
  • RQ represents the relative expression change
  • CT lncRNA and CT ⁇ -actin respectively represent the Ct value of the target lncRNA and the internal reference gene ⁇ -actin in the same sample
  • OC represents patients with neonatal parenteral nutrition-related liver disease
  • ON represents healthy controls
  • Mean ON represents the average value of all normal controls.
  • a negative control and repeated experiments were set up in the experiment. The negative control was the reaction system without cDNA template, replaced by ddH 2 O, and all fluorescent quantitative PCR was repeated 3 times.
  • the relative expression level of lncRNA was analyzed using GraphPad Prism 5 software, using single-sample t-test and independent-sample t-test in the software. When P ⁇ 0.05, the results are considered to be statistically significant. When P ⁇ 0.01, the results are statistically significant.
  • the differentially expressed lncRNA data processing results are expressed as mean ⁇ standard deviation, and a histogram is drawn .
  • lncRNA G034337 The expression level of lncRNA G034337 was detected in 30 PNALD patients and 30 normal healthy newborns. The results showed that lncRNA G034337 was significantly up-regulated in PNALD patients. See attached figure 1, the expression difference is more than 6 times; P ⁇ 0.005.
  • the relative expression levels of lncRNA G034337 in the above-mentioned control group, PNALD group, hyperbilirubinemia group, and fatty liver group are as follows:
  • the specific lncRNA of neonatal parenteral nutrition-related liver disease disclosed in the present invention uses the designed primer pair to perform qRT-PCR method to verify the differential expression, and obtain the specific lncRNA markers of neonatal parenteral nutrition-related liver disease, which has a positive effect on PNALD. It has high application value in diagnosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

新生儿肠外营养相关性肝病特异性标志物lncRNA的应用。lncRNA G034337作为新生儿肠外营养相关性肝病特异性标志物，通过提取新生儿肠外营养相关性肝病患者和健康对照者全血样本的总RNA，设计qRT-PCR特异性引物，并通过常规qRT-PCR检测特异性lncRNA G034337的表达量，结果显示在新生儿肠外营养相关性肝病患儿中lncRNA G034337发生了显著性的上调表达；由此说明，通过检测lncRNA G034337的表达水平，可以有效区分新生儿肠外营养相关性肝病患儿和正常健康人。

Description

新生儿肠外营养相关性肝病特异性标志物lncRNA的应用 技术领域
本发明涉及分子生物学技术领域，尤其涉及一种新生儿肠外营养相关性肝病特异性标志物lncRNA的应用。
背景技术
lncRNA是一类转录本长度大于200bp的非编码RNA产物，在转录、转录后和染色体修饰等多个层面，调控胚胎发育、细胞增殖、转移和分化等各种生命活动，其异常表达与多种疾病的发生发展密切相关。lncRNA有组织特异性与时空特异性，不同组织之间的lncRNA表达量不同，同一组织或器官在不同生长阶段，其中的lncRNA表达量也会变化，lncRNA可从染色质重塑、转录调控及转录后加工等多种层面实现对基因表达的调控。lncRNA启动子同样可以结合转录因子，如Oct3/4、Nanog、CREB、Sp1、c-myc、Sox2与p53，局部染色质组蛋白同样具有特征性的修饰方式与结构特征，序列上保守性较低，只有约12％的lncRNA可在人类之外的其它生物中找到，其作用机制非常复杂，至今尚未完全清楚，比如已有许多研究证实了miRNAs参与调节TGFβ表达量和EMT过程，但参与此过程的lncRNA并不清楚。另外，一些在线网站比如starBase 2.0网站预测准确率低，比如现在已经比较明确的GAS5和miRNA21都预测不到，而且人血清中存在多达1400个lncRNA，还有变化，导致lncRNA无法有效利用。
肠外营养(parenteral nutrition，PN)对不能通过正常肠道方式来满足生长的新生儿带来了革命性关爱。美国自60年代首次报道长期PN应用于一例新生女婴，至今已有数十万患者依赖PN得以生存。但长时间(＞2周)PN应用也存在许多相关问题，肠外营养相关性肝病(total parenteral nutrition-associated liverdisease，PNALD)是一种最常见的并发症，随着长时间PN的应用，PNALD发生率增加，主要表现为肝脂肪变性、胆汁淤积和转氨酶升高。约有30％-60％的患儿因长期PN发生PNALD，伴有肝功能异常和肝细胞损害，严重者发展为肝硬化危及生命。而新生儿发生PNALD更早、肝功能下降更快，死亡率高达38％～51％。因 此，PNALD是严重威胁新生儿健康的重大疾病，如何防治该病是新生儿临床
Figure PCTCN2020093802-appb-000001
待解决的问题。PNALD临床主要表现为黄疸、肝脾肿大，可有白陶土样大便，肝功等化验检查多提示丙氨酸转移酶、天冬氨酸转移酶、碱性磷酸酶、血总胆红素、直接胆红素升高。
因此针对新生儿肠外营养相关性肝病，研发合适的特异性lncRNA作为标志物在调控基因转录、作为疾病诊断标志物等方面具有重要的研究和临床意义。
发明概述
技术问题
本发明提供一种作为针对新生儿肠外营养相关性肝病特异性标志物的lncRNA及其应用。本发明首次公开了lncRNA G034337作为新生儿肠外营养相关性肝病特异性标志物，利用临床上比较容易直接获得的全血标本，结合设计的引物对进行qRT-PCR验证lncRNA的差异表达，具有快速、简单、省时、检测灵敏度高，样品消耗少的优点，是一种准确特异诊断新生儿肠外营养相关性肝病的方法。
问题的解决方案
技术解决方案
本发明的技术方案如下：
lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用；所述lncRNA为lncRNA G034337。
lncRNA在制备新生儿肠外营养相关性肝病特异性标志物中的应用；所述lncRNA为lncRNA G034337。
lncRNA在制备新生儿肠外营养相关性肝病特异性诊断试剂中的应用；所述lncRNA为lncRNA G034337。
本发明中，通过检测人体全血样本中的lncRNA G034337的表达情况即可诊断新生儿肠外营养相关性肝病，与现有临床检测手段结果吻合。
本发明公开了新生儿肠外营养相关性肝病诊断试剂盒，该试剂盒含有能够对lncRNA的表达量进行定量的试剂，所述lncRNA为lncRNA G034337；优选的，所述能够对lncRNA的表达量进行定量的试剂包括qRT-PCR引物对；所述qRT-PCR引 物对的序列为SEQ ID NO：1、SEQ ID NO：2。
本发明还公开了新生儿肠外营养相关性肝病诊断试剂盒在制备新生儿肠外营养相关性肝病诊断试剂中的应用，该试剂盒含有能够对lncRNA的表达量进行定量的试剂，所述lncRNA为lncRNA G034337；优选的，所述能够对lncRNA的表达量进行定量的试剂包括qRT-PCR引物对；所述qRT-PCR引物对的序列为SEQ ID NO：1、SEQ ID NO：2。
本发明公开了能够对lncRNA的表达量进行定量的试剂在制备新生儿肠外营养相关性肝病诊断试剂盒中的应用或者能够对lncRNA的表达量进行定量的试剂在制备新生儿肠外营养相关性肝病诊断试剂中的应用，所述lncRNA为lncRNA G034337；优选的，所述能够对lncRNA的表达量进行定量的试剂包括qRT-PCR引物对；所述qRT-PCR引物对的序列为SEQ ID NO：1、SEQ ID NO：2。
实施例中，本发明通过提取新生儿肠外营养相关性肝病患者和健康对照者全血样本的总RNA，设计qRT-PCR特异性引物，并通过常规qRT-PCR检测特异性lncRNA G034337的表达量，结果显示在新生儿肠外营养相关性肝病患儿中lncRNA G034337发生了显著性的上调表达；由此说明，通过检测lncRNA G034337的表达水平，可以有效区分新生儿肠外营养相关性肝患儿和正常健康人。
本发明中，lncRNA G034337序列为SEQ ID NO：3，具体如下：
Figure PCTCN2020093802-appb-000002
Figure PCTCN2020093802-appb-000003
本发明中，lncRNA相对表达量分析采用GraphPad Prism 5软件，采用软件中单样本T检验和独立样本T检验，P＜0.05时，认为结果在统计学上具有显著性差异，P＜0.01时，结果在统计学上具有极显著性差异。研究发现，相对健康人样本，新生儿肠外营养相关性肝病人lncRNA G034337的表达量都发生了显著性的上调表达，在统计学上具有极显著性差异，可以说明lncRNA G034337可以作为新生儿肠外营养相关性肝病特异性标志物用于诊断。
发明的有益效果
对附图的简要说明
附图说明
图1为lncRNA G034337在PNALD组病人和正常健康人之间的差异表达图；
图2为lncRNA G034337在新生儿高胆红素血症病人和正常健康人之间的差异表达图；
图3为lncRNA G034337在脂肪肝儿童和正常健康人之间的差异表达图。
发明实施例
本发明的实施方式
总RNA提取试剂盒购自Ambion公司；qRT-PCR反转录试剂盒购自Fermentas公司；SYBR system Mix购自TaKaRa宝生物工程(大连)有限公司；384孔板及膜购自罗氏公司。
实施例一新生儿肠外营养相关性肝病人lncRNA G034337的表达量发生了显著性的上调表达
PNALD患儿30例，正常对照组新生儿30例，分别收集外周血3ml，提取血浆中的总RNA，进行qRT-PCR验证。设计及检测结果如下。
本研究经苏州大学附属儿童医院医学伦理委员会批准，PNALD的诊断标准如下：(1)PN持续时间大于等于14天；(2)临床表现为皮肤暗黄并进行性加重、和/或肝脾肿大、大便发白等不能用原发病解释；(3)直接胆红素(DB)＞34.2umol/L(2mg/dL)与DB胆汁淤积反应。(4)排除消化道畸形、遗传性代谢性疾病、先天性病毒感染等明确原因引起的胆汁淤积。正常对照组为健康新生儿，无任何肝脏相关疾病。
qRT-PCR引物为：
Figure PCTCN2020093802-appb-000004
以内参β-actin在新生儿肠外营养相关性肝病患者全血样本中扩增为例，观察扩增情况，扩增曲线平滑且随着循环数的增加，荧光信号具有明显的对数期，而空白对照无连续曲线生成，说明扩增情况良好。对扩增的lncRNA产物做溶解曲线，有且只有一个明显的单峰，而无模板对照无明显波峰出现，说明经扩增后产物是特异的lncRNA，即此定量无污染，准确，可靠。
所有血样采用一次性真空EDTA抗凝采血管抽取，采集外周血3.0mL，颠倒混匀；加入3倍体积红细胞裂解液(300μL血液加入900μL红细胞裂解液)，颠倒 混匀，室温放5min，期间颠倒几次；3000rpm离心5分钟，弃上清。用1mL的红细胞裂解液，轻轻悬浮；3000rpm离心2min，弃上清；用1mL的TRIzol Reagent，轻轻悬浮，-80℃冰箱保存。
将新生儿肠外营养相关性肝病患者和健康对照者含有白细胞的TRIzol Reagent样本于-80℃中取出，待4℃自然溶解；加入等体积酚氯仿，最大转速室温离心5min。取上清；加1.25倍体积100％乙醇；将混合液加入柱子中，室温，13000rpm，30s，弃流过液；加350μL miRNA Wash Solution 1(mirVana TM miRNA ISOlation Kit，Ambion-1561)到离心柱中，13000rpm，30s。弃流过液，将离心柱重新放置到收集管中；混合10μL DNase I和70μL Buffer RDD QIAGEN(#79254)总体积：80μL，加到离心柱中的膜上，室温放置15min；加350μL miRNA Wash Solution 1到离心柱中，13000rpm，30s。弃流过液，将离心柱重新放置到收集管中；500μL Wash Solution 2/3过柱两次，13000rpm，30s。弃流过液，将离心柱重新放置到收集管中；空柱离心1min，将离心柱放置到新的收集管中，柱中心加100μL 95℃预热的Elution Solution，放置2min，室温最高转速离心20-30秒，收集管中的液体即为提取的总RNA，放置在-80℃保存。
取新生儿肠外营养相关性肝病患者和健康对照者总RNA样本1.0μL，经安捷伦生物分析仪器nanodrop-2000检测OD值，在紫外分光光度计上测定A260/A280数值，测定结果总RNA浓度在5～10ng/μL之间，A260/A280数值在1.2～1.9之间，表示总RNA的纯度较好，无蛋白或者时其他有机物的污染亦无总RNA降解。
新生儿肠外营养相关性肝病诊断试剂盒qRT-PCR新生儿肠外营养相关性肝病相关的特异性lncRNA
用Fermentas反转录试剂盒进行反转录，反转录反应体系：总RNA 2.5μL，RNase抑制剂RRI 0.25μL，dNTP(10mM each)0.5μL，5×M-MuLV buffer 1.0μL，随机引物(2μM)0.5μL，M-MuLV反转录酶0.25μL，总体积5μL。分两步方法进行，第一步：65℃，5min；冰上，10min；第二步：42℃，60min；70℃，15min；反应完毕后，保存于-80℃冰箱。
QRT-PCR体系：ddH 2O7μL，SYBR system Mix 10μL，50*ROX refenence dye 0.4μL，上游引物(10μM)/下游引物(10μM)0.8μL，模板cDNA1μL，总体 积20μL；混匀后离心，在ABI 7500中进行荧光定量PCR反应，反应参数设置为：95℃ 30s，然后95℃ 5s，60℃ 31s，共40个循环。
lncRNA荧光定量数据分析以β-actin为内参基因，对目标基因进行归一化处理，已确保相等数量的样品中比较目标基因的量。lncRNA表达倍数的变化公式为RQ＝2 -ΔΔCT，其中ΔΔCT＝(CT lncRNA-CT β-actin)OC-(CT lncRNA-CT β-actin)Mean ON。RQ代表相对表达变化量，CT lncRNA和CT β-actin分别代表同个样本中目标lncRNA和内参基因β-actin的Ct值，OC代表新生儿肠外营养相关性肝病患者，ON代表健康对照者，Mean ON代表所有正常对照组中的平均值。实验设立阴性对照和重复实验，阴性对照为反应体系中不加cDNA模板，以ddH 2O代替，所有荧光定量PCR均做3次重复。lncRNA相对表达量分析采用GraphPad Prism 5软件，采用软件中单样本t检验和独立样本t检验。P＜0.05时，认为结果在统计学上具有显著性差异，P＜0.01时，结果在统计学上具有极显著性差异，差异表达的lncRNA数据处理结果以平均值±标准差表示，绘制柱状图。
分别在30例PNALD病人和30例正常健康新生儿中检测lncRNA G034337的表达量，结果显示在PNALD病人中lncRNA G034337发生了显著性的上调表达，见附图1，表达差异在6倍以上；P＜0.005。
实施例二验证lncRNA G034337的表达特异性
经苏州大学附属儿童医院医学伦理委员会批准，收集30例临床确诊的新生儿高胆红素血症患儿，明确为非PNALD患者。根据实施例一同样的方法检测外周血以分析lncRNA G034337在该病的表达情况，结果表明，与对照组(正常健康，实施例一)相比，lncRNA G034337在新生儿高胆红素血症患儿血浆中表达量无明显差异，差异无统计学意义；P＞0.05，见图2。
实施例三验证lncRNA G034337的表达特异性
经苏州大学附属儿童医院医学伦理委员会批准，收集30例临床确诊脂肪肝患儿(0-14岁)，明确为非PNALD患者。根据实施例一同样的方法检测外周血以分析lncRNA G034337在该病的表达情况，结果表明，与对照组(正常健康，实施例一)相比，lncRNA G034337在脂肪肝患儿血浆中表达量无明显差异，差异无统计学意义；P＞0.05，见图3。
上述对照组、PNALD组、高胆红素血症组、脂肪肝组lncRNA G034337的相对表达量如下：
对照组 PNALD组 高胆红素血症组 脂肪肝组
1.32 6.94 1.82 1.65
1.84 6.75 1.26 1.35
1.19 7.17 1.44 1.41
1.11 7.26 1.12 1.45
1.68 6.65 1.65 1.48
1.47 6.54 1.60 1.40
1.27 6.37 1.17 1.50
1.54 7.13 1.64 1.64
1.65 6.68 1.05 1.37
1.35 7.13 1.18 1.84
0.91 5.99 1.05 1.59
1.80 7.52 1.50 1.57
1.12 6.74 1.74 1.42
1.29 7.44 1.44 1.30
1.54 7.76 1.40 1.04
1.41 6.42 1.33 1.82
1.53 7.13 1.50 1.38
1.31 8.00 1.26 1.28
1.09 6.37 1.36 1.33
1.65 6.91 1.31 1.49
1.36 7.36 1.36 1.64
1.42 7.02 1.19 1.17
1.29 5.94 1.61 1.34
1.34 8.31 1.69 1.43
1.59 6.63 1.50 1.26
1.56 7.29 1.35 1.44
1.25 7.27 1.22 1.36
1.49 7.38 1.69 1.56
1.21 6.86 1.16 1.13
1.44 8.12 1.43 1.36
。
本发明公开的新生儿肠外营养相关性肝病特异性lncRNA，利用设计的引物对进行qRT-PCR方法验证得到差异表达量，获得新生儿肠外营养相关性肝病特异性lncRNA标志物，对PNALD的诊断上具有较高的应用价值。

Claims (10)

  1. lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用；所述lncRNA为lncRNA G034337。
  2. lncRNA在制备新生儿肠外营养相关性肝病特异性标志物中的应用；所述lncRNA为lncRNA G034337。
  3. lncRNA在制备新生儿肠外营养相关性肝病特异性诊断试剂中的应用；所述lncRNA为lncRNA G034337。
  4. 新生儿肠外营养相关性肝病诊断试剂盒，所述试剂盒含有能够对lncRNA的表达量进行定量的试剂，所述lncRNA为lncRNA G034337。
  5. 根据权利要求4所述新生儿肠外营养相关性肝病诊断试剂盒，其特征在于，所述能够对lncRNA的表达量进行定量的试剂包括qRT-PCR引物对；所述qRT-PCR引物对的序列为SEQ ID NO：1、SEQ ID NO：2。
  6. 根据权利要求4所述新生儿肠外营养相关性肝病诊断试剂盒，其特征在于，所述lncRNA G034337的序列为SEQ ID NO：3。
  7. 权利要求4所述新生儿肠外营养相关性肝病诊断试剂盒在制备新生儿肠外营养相关性肝病诊断试剂中的应用。
  8. 能够对lncRNA的表达量进行定量的试剂在制备新生儿肠外营养相关性肝病诊断试剂盒中的应用或者能够对lncRNA的表达量进行定量的试剂在制备新生儿肠外营养相关性肝病诊断试剂中的应用，所述lncRNA为lncRNA G034337。
  9. 根据权利要求8所述的应用，其特征在于，所述能够对lncRNA的表达量进行定量的试剂包括qRT-PCR引物对；所述QRT-PCR引物对的序列为SEQ ID NO：1、SEQ ID NO：2。
  10. 根据权利要求1、2、3、7或者8所述的应用，其特征在于，所述lncRNA G034337的序列为SEQ ID NO：3。
PCT/CN2020/093802 2020-06-01 2020-06-01 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用 WO2021243526A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/093802 WO2021243526A1 (zh) 2020-06-01 2020-06-01 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/093802 WO2021243526A1 (zh) 2020-06-01 2020-06-01 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用

Publications (1)

Publication Number Publication Date
WO2021243526A1 true WO2021243526A1 (zh) 2021-12-09

Family

ID=78830089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/093802 WO2021243526A1 (zh) 2020-06-01 2020-06-01 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用

Country Status (1)

Country Link
WO (1) WO2021243526A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091019A1 (en) * 2010-01-19 2011-07-28 University Of Tennessee Research Foundation Methods and compositions for treating and preventing parenteral nutrition associated liver disease
CN107308178A (zh) * 2017-07-31 2017-11-03 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物
CN107446952A (zh) * 2017-07-31 2017-12-08 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物的制备方法
WO2018085622A1 (en) * 2016-11-04 2018-05-11 Children's Hospital Medical Center Liver organoid disease models and methods of making and using same
WO2020061114A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
CN111093399A (zh) * 2017-08-10 2020-05-01 儿童医疗中心有限公司 与包含鱼油和/或ω-3脂肪酸的乳剂有关的方法和组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091019A1 (en) * 2010-01-19 2011-07-28 University Of Tennessee Research Foundation Methods and compositions for treating and preventing parenteral nutrition associated liver disease
WO2018085622A1 (en) * 2016-11-04 2018-05-11 Children's Hospital Medical Center Liver organoid disease models and methods of making and using same
CN107308178A (zh) * 2017-07-31 2017-11-03 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物
CN107446952A (zh) * 2017-07-31 2017-12-08 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物的制备方法
CN111093399A (zh) * 2017-08-10 2020-05-01 儿童医疗中心有限公司 与包含鱼油和/或ω-3脂肪酸的乳剂有关的方法和组合物
WO2020061114A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Similar Documents

Publication Publication Date Title
Puppala et al. Primate fetal hepatic responses to maternal obesity: epigenetic signalling pathways and lipid accumulation
Camkurt et al. Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls
Chen et al. Increased salivary microRNAs that regulate DJ-1 gene expression as potential markers for Parkinson’s disease
Zeng et al. Potential microRNA biomarkers for acute ischemic stroke
US20200270690A1 (en) Serum/plasma LncRNA marker composition associated with auxiliary diagnosis of intrahepatic cholestasis of pregnancy and application thereof
Wang et al. Function and mechanism of microRNA‑210 in acute cerebral infarction
Onrat et al. The genetic determination of the differentiation between ischemic dilated cardiomyopathy and idiopathic dilated cardiomyopathy
US20050214820A1 (en) Diagnosis of sepsis using mitochondrial nucleic acid assays
Liu et al. Effect of long-term exercise training on lncRNAs expression in the vascular injury of insulin resistance
WO2021243782A1 (zh) 用于诊断肝癌和预测肝癌转移的血清miRNA标志物及其检测试剂盒
Miao et al. Hsa_circ_0046159 is involved in the development of chronic thromboembolic pulmonary hypertension
CN107653315B (zh) lncRNAs作为活动性肺结核病特异性标志物的应用
Świtlik et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: a preliminary study
Szczerba et al. Downregulated expression of microRNAs associated with cardiac hypertrophy and fibrosis in physiological pregnancy and the association with echocardiographically‑evaluated myocardial function
WO2021232573A1 (zh) lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用
WO2021243526A1 (zh) 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用
Shahouzehi et al. Serum microRNA-33 levels in pre-diabetic and diabetic patients
Feng et al. Clinical significance of microRNA-146a in patients with ulcerative colitis
Jiang et al. Resveratrol inhibits cell apoptosis by suppressing long noncoding RNA (lncRNA) XLOC_014869 during lipopolysaccharide-induced acute lung injury in rats
Mohsen et al. Association of miR-499 Gene Polymorphism with Some Hormones in type 2 Diabetes Mellitus Patients.
CN107190075A (zh) 用于mRNA检测的试剂及用途
Yang et al. Serum MicroRNA Profiling and Bioinformatics of Patients with Spleen‐Deficiency Syndrome
Monfared et al. Determination and comparison miR 5a in the serum between women with GDM, non-pregnant type diabetes, healthy pregnant and control group
Ma et al. Tetralogy of Fallot: aorto-pulmonary collaterals and pulmonary arteries have distinctly different transcriptomes
US11685950B2 (en) Method of diagnosing and treating acute rejection in kidney transplant patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20938955

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20938955

Country of ref document: EP

Kind code of ref document: A1